Market Overview

Somaxon Reports Paladin Labs Wins Health Canada Approval of NDS for Silenor

Related SOMX
Pernix Therapeutics Completes Acquisition of Somaxon Pharmaceuticals
Morning Market Movers

Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX) today announced that its licensee Paladin Labs Inc. has received approval from Health Canada of Paladin's New Drug Submission (NDS) for Silenor^® (doxepin) for the treatment and symptomatic relief of insomnia characterized by frequent nocturnal awakening and/or early morning awakenings.

Posted-In: News FDA


Related Articles (SOMX)

View Comments and Join the Discussion!

Partner Center